Stock·NASDAQ·Healthcare
Tempus AI Inc (TEM)
- Market cap
- $12.83B
- Dividend yield
- 0.00%
- Street target
- $75.00median of 20 analysts
- 52-week range
- $40.77 $96.29
The short version
Where TEM stands today, in four lines, and what CleaRank Financial AI makes of it.
TEM at a glance
Tempus AI Inc (TEM): Hold, 55/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($56.79 and $67.84).
- Earnings TEM beat estimates in 7 of its last 8 quarters, yet fell the next day after 6 of those beats.
- Insiders Insiders sold $333.7M and made no open-market purchases over the last 18 months.
Figures as of October 16, 2026.
CleaRank Financial AI
Tempus AI Inc. (TEM) is currently trading at $65.70, below its 50-day SMA of $67.84 but above its 200-day SMA of $56.79.
The company has demonstrated impressive revenue growth, with current year estimates at +25.00% and next year projected at +23.00%. Wall Street analysts maintain a generally positive outlook, with a consensus rating of 'Buy' and a median price target of $75.00, suggesting an upside of 14.2% from current levels. However, significant headwinds exist. The company reports negative profitability across the board, with a net profit margin of -17.77% and a return on equity of -67.44%. Also, insider activity reveals a heavy insider selling with over $333.7 million in total sales and no reported purchases. This heavy insider selling, coupled with negative EPS in recent quarters, presents a substantial risk to the stock's near-term performance.
Only on CleaRank
Figures we compute ourselves from TEM's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
2/4Price above its 50-day average ›
The price of $65.70 is 3.1% below the 50-day simple moving average of $67.84.Price above its 200-day average ›
The price is 15.7% above the 200-day simple moving average of $56.79.50-day average above the 200-day ›
The 50-day average ($67.84) is 19.4% above the 200-day average ($56.79), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 45% of its 52-week range, between $40.77 and $96.29.
TEM share price
Pick a period: each tab shows how far TEM has moved over it, to the last close.
Today's trading
Where TEM sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
1/3P/S below the sector median ›
The price-to-sales ratio of 8.61 is 153.2% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $-254.4M on revenue of $1.4B, a net margin of -17.8%.Beat estimates in most recent reports ›
TEM beat the EPS estimate in 7 of its last 8 reports.
Key statistics
The headline figures for TEM.
As of October 16, 2026, TEM trades at $65.70, with a market value of $12.83B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of TEM's valuation, growth and risks.
Tempus AI Inc. exhibits a Price-to-Sales ratio of 8.61, which is considerably higher than the sector median of 3.4, suggesting the stock may be overvalued relative to its revenue.
The company's profitability metrics are significantly negative, with a net profit margin of -17.77% and a return on equity of -67.44%, significantly underperforming the sector median ROE of 7.3%. Despite these weak profitability figures, revenue growth remains strong at 21.6% year-over-year, with forward estimates projecting continued expansion. The company's debt-to-equity ratio stands at 3.25, which is high and warrants attention, especially given the negative earnings. The current valuation appears stretched when considering the lack of profitability and high debt levels, even with strong revenue growth.
TEM against the Healthcare sector
How TEM compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, TEM trades at 8.61x, +153% versus the sector average of 3.40x.
Return vs XLV: Since May 5, 2025, TEM has gained 31.6% against a gain of 28.3% for XLV.
Performance against XLV
TEM and the Healthcare sector fund over the same days.
Revenue and earnings
How much TEM sells, and how much of it becomes profit.
Revenue growth: Revenue grew 83.4% in FY2025 to $1.3B, from $693M a year earlier.
Profit margin: The net margin was -19.3% in FY2025, up from -101.8% the year before.
Profitable: TEM lost $245M in FY2025.
Earnings reality check
Did TEM beat what analysts expected, and how did the stock react?
Earnings record: TEM beat the analyst estimate in 7 of the last 8 quarters.
Market reaction: The stock fell in the first session after 6 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 30, 2026after close | -$0.15 | -$0.04 | +73.33% | -0.95% | +4.13% |
| May 5, 2026after close | -$0.20 | -$0.13 | +35.00% | -1.05% | -13.17% |
| Nov 4, 2025after close | -$0.18 | -$0.11 | +38.89% | -2.64% | -15.30% |
| Aug 8, 2025after close | -$0.25 | -$0.22 | +12.00% | -0.08% | +21.21% |
| May 6, 2025after close | -$0.27 | -$0.24 | +11.11% | +12.59% | +32.04% |
| Feb 24, 2025after close | -$0.15 | -$0.18 | -20.00% | -15.05% | -26.79% |
| Nov 4, 2024after close | -$0.31 | -$0.25 | +19.35% | -10.10% | +56.81% |
| Aug 6, 2024after close | -$1.79 | -$0.63 | +64.80% | -0.46% | +21.24% |
As of October 16, 2026, TEM has beaten the analyst EPS estimate in 7 of its last 8 reported quarters and fell in the first trading session after 6 of those beats; its latest report, on July 30, 2026, came in 73.33% above the estimate and the stock moved -0.95% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 42.5, in neutral territory.RSI above 50 ›
An RSI of 42.5 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of TEM
The score, the reasoning behind it, and what could move the price next.
Tempus AI Inc. is currently trading below its 20-day EMA ($71.71) and 50-day SMA ($67.84), indicating short-term downward pressure.
However, the price remains above its 200-day SMA ($56.79), suggesting a longer-term uptrend is still intact. The 14-day RSI is at 42.53, falling into the neutral momentum category, offering no strong signal of overbought or oversold conditions. Key support is observed around the 200-day SMA at $56.79, while resistance lies near the 20-day EMA at $71.71 and the 50-day SMA at $67.84. The current technical setup indicates a stock in consolidation, with potential for a pullback towards its longer-term moving average if selling pressure persists.
Strong Revenue Growth Projections ›
Forward estimates indicate continued strong revenue expansion, with current year growth projected at +25.00% and next year at +23.00%, suggesting market demand for its services.
Source: Wall Street EstimatesPositive Earnings Surprises ›
Recent quarters have shown positive surprises in EPS estimates, indicating that the company is exceeding analyst expectations on an earnings basis, although this has not translated to price appreciation.
Source: Company Earnings Reports
Heavy Insider Selling Continues ›
Insiders have sold over $333.7 million in stock with no reported purchases.
Source: Insider Trading DataPersistent Negative Profitability ›
The company continues to report substantial net losses (-17.77% profit margin) and negative EPS, raising concerns about its path to profitability despite strong revenue growth.
Source: Company Financials
- Monitor insider transaction activity closely; the current heavy insider selling with over $333.7 million in sales is a significant concern that outweighs positive revenue growth.
- Given the stock is trading below its 20-day EMA and 50-day SMA, consider waiting for a technical confirmation of support before entering a long position.
- The company's high Price-to-Sales ratio (8.61) and negative profit margins suggest that investors are pricing in substantial future growth; any slowdown in revenue expansion could lead to a sharp valuation correction.
Technical indicators
Momentum and trend for TEM, from its daily closes.
As of October 16, 2026, with TEM at $65.70, its 14-day RSI is 42.5 (neutral territory), its 50-day simple moving average is $67.84 and its 200-day is $56.79.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What TEM moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, TEM's 1-year correlation of daily returns is +0.47 with S&P 500 (SPY), +0.46 with Nasdaq 100 (QQQ), +0.32 with Bitcoin (BTC) and +0.15 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
10 of 20 analysts rate it a buy or strong buy, 9 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $75.00 is 14.2% above the price.More buy ratings than three months ago ›
10 of 20 rate it a buy now, against 8 of 16 three months ago.
TEM Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 12, 2026 | Canaccord Genuity | Maintains | Buy |
| Oct 1, 2026 | Guggenheim | Maintains | Buy |
| Sep 21, 2026 | Goldman Sachs | Initiates | Neutral |
| Sep 11, 2026 | HC Wainwright & Co. | Maintains | Buy |
| Sep 9, 2026 | UBS | Initiates | Neutral |
| Sep 8, 2026 | Rothschild & Co | Initiates | Neutral |
As of October 16, 2026, 20 Wall Street analysts cover TEM: 10 rate it a buy or strong buy, 9 a hold and 1 a sell or strong sell. Their 12-month price targets range from $35.00 to $100.00, with a median of $75.00, 14.2% above the price of $65.70.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
TEM trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
TEM moves about 5.6% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much TEM tends to move, against the market and on its own.
The long record
TEM's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/3Average daily move under 2% ›
The price has moved 5.61% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 59.8%, from October 2025 to July 2026; the price is still 36.4% below that peak.Beat the S&P 500 since the chart begins ›
$10,000 invested in June 2024 is now worth $17,672, against $14,638 in the S&P 500 (SPY).
TEM Drawdowns & Recovery
As of October 16, 2026, TEM's worst peak-to-trough fall over the last 2 years with dividends reinvested was -59.8% (October 2025 to July 2026); it is still 36.4% below that peak.
From daily closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into TEM in June 2024 is worth now, against the same amount in the S&P 500.
Against the market: TEM beat the S&P 500 over this period: $17,672 against $14,638.
A $10,000 investment in TEM in June 2024 would be worth about $17,672 today with dividends reinvested, compared with about $14,638 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to TEM, and which have not.
Strongest month, August: an average of +40.79%.
Weakest month, December: an average of -33.32%.
This month, October: has averaged -6.90%. Past seasonality does not repeat on schedule.
Average return for each calendar month over the stored price history; treat short histories with caution.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in TEM, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in TEM today could grow to about $25,273 by 2036 in the base case, with a 90th-percentile outcome near $191,737 and a 10th-percentile outcome around $3,331. Projections are statistical simulations, not guarantees.
TEM Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $95.20 for TEM by 2030 in the base case, from $65.70 today (1.4x over 4 years). The 10th-percentile path ends near $26.43. These are outcomes of a Monte Carlo simulation run on TEM's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $37.98 | $72.08 | $137 | |
| 2028 | $31.95 | $79.09 | $196 | |
| 2029 | $28.60 | $86.77 | $263 | |
| 2030 | $26.43 | $95.20 | $343 | |
| 2031 | $24.92 | $104 | $438 |
Method: a lognormal simulation of TEM's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. TEM is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation.
Insider trading
What the people running the company have bought and sold.
TEM insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought TEM shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 16, 2026, TEM insiders reported 99 open-market sales worth $333.7M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 25, 2026 | Thomas Edward Schoenherr
Officer
|
Sell | 10.3K | $873.9K |
| Sep 22, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 250.0K | $19.4M |
| Sep 1, 2026 | Ryan Fukushima
Officer
|
Sell | 30.8K | $1.9M |
| Sep 1, 2026 | Jennifer A. Ph.d. Doudna
Director
|
Sell | 676 | $44.3K |
| Sep 1, 2026 | David R Epstein
Director
|
Sell | 250 | $16.4K |
| Aug 28, 2026 | Nadja Y. West
Director
|
Sell | 3.0K | $207.0K |
| Aug 25, 2026 | Eric Paul Lefkofsky
Chairman of the Board
|
Sell | 238.2K | $16.3M |
| Aug 25, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 11.8K | $827.9K |
| Aug 21, 2026 | Ryan Fukushima
Officer
|
Sell | 14.3K | $1.0M |
| Aug 21, 2026 | Thomas Edward Schoenherr
Officer
|
Sell | 2.7K | $188.6K |
| Aug 19, 2026 | James William Rogers
Chief Financial Officer
|
Sell | 48.8K | $2.7M |
| Aug 19, 2026 | Andrew Polovin
Officer
|
Sell | 30.1K | $1.5M |
| Aug 19, 2026 | Thomas Edward Schoenherr
Officer
|
Sell | 17.3K | $930.0K |
| Aug 18, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 132.6K | $6.6M |
| Aug 18, 2026 | Ryan Fukushima
Officer
|
Sell | 41.1K | $2.0M |
| Aug 18, 2026 | Ryan M Bartolucci
Officer
|
Sell | 6.2K | $306.3K |
| Aug 14, 2026 | Nadja Y. West
Director
|
Sell | 3.0K | $161.7K |
| Aug 12, 2026 | Ryan Fukushima
Officer
|
Grant | 62.2K | - |
| Aug 7, 2026 | Ryan Fukushima
Officer
|
Sell | 20.0K | $1.0M |
| Aug 3, 2026 | Ryan Fukushima
Officer
|
Sell | 23.8K | $1.1M |
| Aug 3, 2026 | David R Epstein
Director
|
Sell | 370 | $16.1K |
| Jul 29, 2026 | Andrew Polovin
Officer
|
Grant | 40.0K | - |
| Jul 29, 2026 | James William Rogers
Chief Financial Officer
|
Grant | 40.0K | - |
| Jul 28, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 250.0K | $10.5M |
| Jul 8, 2026 | Ryan Fukushima
Officer
|
Sell | 33.3K | $1.9M |
| Jul 6, 2026 | Ryan Fukushima
Officer
|
Sell | 10.0K | $600.0K |
| Jun 29, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $9.6M |
| Jun 25, 2026 | James William Rogers
Chief Financial Officer
|
Sell | 11.5K | $634.1K |
| Jun 25, 2026 | Jennifer A. Ph.d. Doudna
Director
|
Sell | 2.7K | $147.0K |
| Jun 1, 2026 | David R Epstein
Director
|
Sell | 250 | $12.4K |
| May 27, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $7.8M |
| May 21, 2026 | Eric D Belcher
Director
|
Grant | 5.9K | - |
| May 21, 2026 | Jennifer A. Ph.d. Doudna
Director
|
Grant | 5.9K | - |
| May 21, 2026 | David R Epstein
Director
|
Grant | 5.9K | - |
| May 21, 2026 | Wayne A.i. Frederick
Director
|
Grant | 5.9K | - |
| May 21, 2026 | Scott Gottlieb
Director
|
Grant | 5.9K | - |
| May 21, 2026 | Theodore J Leonsis
Director
|
Grant | 5.9K | - |
| May 21, 2026 | Nadja Y. West
Director
|
Grant | 5.9K | - |
| May 19, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 22.3K | $984.3K |
| May 19, 2026 | Ryan Fukushima
Officer
|
Sell | 13.6K | $597.1K |
| May 19, 2026 | James William Rogers
Chief Financial Officer
|
Sell | 10.9K | $478.3K |
| May 19, 2026 | Andrew Polovin
Officer
|
Sell | 8.7K | $383.5K |
| May 19, 2026 | Ryan M Bartolucci
Officer
|
Sell | 4.1K | $181.4K |
| May 19, 2026 | Thomas Edward Schoenherr
Officer
|
Sell | 1.6K | $69.6K |
| May 14, 2026 | Ryan Fukushima
Officer
|
Grant | 162.2K | - |
| May 4, 2026 | Ryan M Bartolucci
Officer
|
Grant | 24.0K | - |
| May 4, 2026 | Ryan Fukushima
Officer
|
Grant | 10.0K | - |
| May 4, 2026 | Andrew Polovin
Officer
|
Grant | 10.0K | - |
| May 4, 2026 | James William Rogers
Chief Financial Officer
|
Grant | 10.0K | - |
| May 4, 2026 | Thomas Edward Schoenherr
Officer
|
Grant | 13.6K | - |
| Apr 28, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $8.5M |
| Mar 26, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $7.7M |
| Mar 2, 2026 | James William Rogers
Chief Financial Officer
|
Sell | 11.4K | $578.6K |
| Mar 2, 2026 | David R Epstein
Director
|
Sell | 250 | $12.7K |
| Feb 20, 2026 | Andrew Polovin
Officer
|
Sell | 19.1K | $1.1M |
| Feb 20, 2026 | Ryan M Bartolucci
Officer
|
Grant | 13.0K | - |
| Feb 20, 2026 | Ryan Fukushima
Officer
|
Grant | 75.0K | - |
| Feb 20, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Grant | 263.4K | - |
| Feb 20, 2026 | Andrew Polovin
Officer
|
Grant | 38.4K | - |
| Feb 20, 2026 | James William Rogers
Chief Financial Officer
|
Grant | 37.5K | - |
| Feb 19, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 179.8K | $10.6M |
| Feb 19, 2026 | James William Rogers
Chief Financial Officer
|
Sell | 10.1K | $595.5K |
| Feb 19, 2026 | Ryan Fukushima
Officer
|
Sell | 9.6K | $566.4K |
| Feb 19, 2026 | Erik J. Phelps
Officer
|
Sell | 9.5K | $562.5K |
| Feb 19, 2026 | Ryan M Bartolucci
Officer
|
Sell | 2.9K | $171.4K |
| Feb 2, 2026 | David R Epstein
Director
|
Sell | 370 | $22.0K |
| Jan 28, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $10.9M |
| Jan 5, 2026 | Ryan Fukushima
Chief Operating Officer
|
Sell | 5.0K | $321.3K |
| Jan 2, 2026 | Jennifer A. Ph.d. Doudna
Director
|
Sell | 1.3K | $75.2K |
| Dec 18, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $10.6M |
| Dec 16, 2025 | Erik J. Phelps
Officer
|
Sell | 1.3K | $87.8K |
| Dec 11, 2025 | James William Rogers
Chief Financial Officer
|
Sell | 20.0K | $1.5M |
| Dec 5, 2025 | Frederick Wayne
Director
|
Sell | 3.7K | $283.8K |
| Dec 1, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 5.0K | $378.6K |
| Dec 1, 2025 | Jennifer A. Ph.d. Doudna
Director
|
Sell | 676 | $51.1K |
| Dec 1, 2025 | David R Epstein
Director
|
Sell | 250 | $18.9K |
| Nov 25, 2025 | Ryan Fukushima
Chief Operating Officer
|
Grant | 257.0K | - |
| Nov 24, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $12.3M |
| Nov 24, 2025 | Andrew Polovin
General Counsel
|
Sell | 12.9K | $965.6K |
| Nov 20, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 183.1K | $12.6M |
| Nov 19, 2025 | Andrew Polovin
General Counsel
|
Sell | 11.6K | $775.8K |
| Nov 18, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 10.1K | $661.9K |
| Nov 18, 2025 | James William Rogers
Chief Financial Officer
|
Sell | 7.3K | $475.6K |
| Nov 18, 2025 | Erik J. Phelps
Officer
|
Sell | 3.5K | $231.5K |
| Nov 18, 2025 | Ryan M Bartolucci
Officer
|
Sell | 1.8K | $120.2K |
| Nov 11, 2025 | Jennifer A. Ph.d. Doudna
Director
|
Sell | 1.9K | $137.6K |
| Nov 3, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 5.0K | $445.2K |
| Nov 3, 2025 | David R Epstein
Director
|
Sell | 370 | $33.3K |
| Oct 28, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 332.5K | $29.6M |
| Oct 6, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 5.0K | $461.6K |
| Sep 25, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 332.5K | $25.5M |
| Sep 2, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 10.0K | $758.0K |
| Sep 2, 2025 | David R Epstein
Director
|
Sell | 250 | $18.4K |
| Aug 27, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 332.5K | $24.6M |
| Aug 26, 2025 | Theodore J Leonsis
Director
|
Sell | 20.0K | $1.5M |
| Aug 19, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 17.5K | $1.3M |
| Aug 19, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 17.5K | $1.3M |
| Aug 19, 2025 | James William Rogers
Chief Financial Officer
|
Sell | 7.5K | $562.0K |
| Aug 19, 2025 | Andrew Polovin
General Counsel
|
Sell | 5.4K | $403.0K |
| Aug 19, 2025 | Erik J. Phelps
Officer
|
Sell | 3.7K | $273.5K |
| Aug 19, 2025 | Ryan M Bartolucci
Officer
|
Sell | 1.9K | $142.1K |
| Aug 13, 2025 | Theodore J Leonsis
Director
|
Sell | 44.0K | $3.1M |
| Aug 1, 2025 | David R Epstein
Director
|
Sell | 370 | $20.4K |
| Jul 28, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $10.5M |
| Jul 7, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 5.0K | $300.0K |
| Jul 1, 2025 | Jennifer A. Ph.d. Doudna
Director
|
Sell | 625 | $39.1K |
| Jun 18, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 500.0K | $34.9M |
| Jun 16, 2025 | Erik J. Phelps
Officer
|
Sell | 51.3K | $3.7M |
| Jun 16, 2025 | Andrew Polovin
General Counsel
|
Sell | 1.4K | $102.6K |
| Jun 11, 2025 | Theodore J Leonsis
Director
|
Sell | 205.8K | $13.9M |
| Jun 3, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 20.0K | $1.2M |
| Jun 2, 2025 | Jennifer A. Ph.d. Doudna
Director
|
Sell | 558 | $30.8K |
| Jun 2, 2025 | David R Epstein
Director
|
Sell | 250 | $13.8K |
| May 20, 2025 | James William Rogers
Chief Financial Officer
|
Sell | 23.1K | $1.5M |
| May 20, 2025 | Andrew Polovin
General Counsel
|
Sell | 17.6K | $1.1M |
| May 20, 2025 | Erik J. Phelps
Officer
|
Sell | 8.4K | $531.9K |
| May 20, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 7.8K | $494.3K |
| May 20, 2025 | Ryan M Bartolucci
Officer
|
Sell | 6.1K | $384.0K |
| May 20, 2025 | Eric D Belcher
Director
|
Grant | 2.0K | - |
| May 20, 2025 | Jennifer A. Ph.d. Doudna
Director
|
Grant | 2.0K | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.